Published in J Mol Biol on February 04, 2011
The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. Biochemistry (2011) 1.03
Hexafluoroisopropanol induces amyloid fibrils of islet amyloid polypeptide by enhancing both hydrophobic and electrostatic interactions. J Biol Chem (2011) 0.96
A new prion disease: relationship with central and peripheral amyloidoses. Nat Rev Neurol (2015) 0.87
Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation. J Biol Chem (2012) 0.83
Benzalkonium chloride accelerates the formation of the amyloid fibrils of corneal dystrophy-associated peptides. J Biol Chem (2013) 0.83
Amyloidogenic propensity of a natural variant of human apolipoprotein A-I: stability and interaction with ligands. PLoS One (2015) 0.79
Myeloperoxidase-mediated Methionine Oxidation Promotes an Amyloidogenic Outcome for Apolipoprotein A-I. J Biol Chem (2015) 0.78
Insights into human phosphoglycerate kinase 1 deficiency as a conformational disease from biochemical, biophysical, and in vitro expression analyses. J Inherit Metab Dis (2014) 0.76
Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes. J Biol Chem (2015) 0.76
Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells. J Cell Mol Med (2011) 0.76
Conformational and aggregation properties of the 1-93 fragment of apolipoprotein A-I. Protein Sci (2014) 0.76
sw ApoMb Amyloid Aggregation under Nondenaturing Conditions: The Role of Native Structure Stability. Biophys J (2017) 0.75
Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem (2006) 22.87
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature (2002) 10.81
Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Simultaneous determination of protein structure and dynamics. Nature (2005) 5.28
Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) (2003) 5.15
Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature (2003) 4.98
The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci U S A (2002) 4.08
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Long-range interactions within a nonnative protein. Science (2002) 4.06
Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell (2011) 3.98
Protein structure determination from NMR chemical shifts. Proc Natl Acad Sci U S A (2007) 3.96
An analytical solution to the kinetics of breakable filament assembly. Science (2009) 3.87
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
Amyloid formation by globular proteins under native conditions. Nat Chem Biol (2009) 3.72
High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy. Proc Natl Acad Sci U S A (2004) 3.58
Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell (2012) 3.39
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J Mol Biol (2005) 3.18
Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc (2005) 3.13
Role of intermolecular forces in defining material properties of protein nanofibrils. Science (2007) 2.94
Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A (2013) 2.89
Low-populated folding intermediates of Fyn SH3 characterized by relaxation dispersion NMR. Nature (2004) 2.84
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
A primer of amyloid nomenclature. Amyloid (2007) 2.70
The importance of sequence diversity in the aggregation and evolution of proteins. Nature (2005) 2.70
De novo designed peptide-based amyloid fibrils. Proc Natl Acad Sci U S A (2002) 2.59
The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J (2002) 2.59
Prediction of aggregation-prone regions in structured proteins. J Mol Biol (2008) 2.56
A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol (2010) 2.48
Characterization of the nanoscale properties of individual amyloid fibrils. Proc Natl Acad Sci U S A (2006) 2.46
Molecular recycling within amyloid fibrils. Nature (2005) 2.39
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
Kinetic partitioning of protein folding and aggregation. Nat Struct Biol (2002) 2.37
Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity. PLoS Biol (2007) 2.35
Structure of an intermediate state in protein folding and aggregation. Science (2012) 2.24
Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood (2009) 2.19
Molecular conformation of a peptide fragment of transthyretin in an amyloid fibril. Proc Natl Acad Sci U S A (2002) 2.18
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J Mol Biol (2009) 2.14
Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. J Mol Biol (2004) 2.14
Relation between native ensembles and experimental structures of proteins. Proc Natl Acad Sci U S A (2006) 2.10
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation (2009) 1.93
Myoglobin forms amyloid fibrils by association of unfolded polypeptide segments. Proc Natl Acad Sci U S A (2003) 1.93
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation (2003) 1.93
Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid (2010) 1.91
Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid (2014) 1.91
Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci (2006) 1.89
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Biochem Sci (2007) 1.88
Predicting protein associations with long noncoding RNAs. Nat Methods (2011) 1.88
Determination of secondary structure populations in disordered states of proteins using nuclear magnetic resonance chemical shifts. Biochemistry (2012) 1.87
Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. Proc Natl Acad Sci U S A (2004) 1.83
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
International prognostic scoring system for Waldenstrom macroglobulinemia. Blood (2009) 1.81
The Zyggregator method for predicting protein aggregation propensities. Chem Soc Rev (2008) 1.81
Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc Natl Acad Sci U S A (2002) 1.80
The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J (2007) 1.79
Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem (2004) 1.79
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J (2012) 1.77
Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med (2007) 1.75
Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proc Natl Acad Sci U S A (2013) 1.75
Fast and accurate predictions of protein NMR chemical shifts from interatomic distances. J Am Chem Soc (2009) 1.75
Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci U S A (2010) 1.72
From macroscopic measurements to microscopic mechanisms of protein aggregation. J Mol Biol (2012) 1.71
Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput Biol (2007) 1.71
Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis (2013) 1.68
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature (2003) 1.66
The MUMO (minimal under-restraining minimal over-restraining) method for the determination of native state ensembles of proteins. J Biomol NMR (2007) 1.65
Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat Struct Biol (2002) 1.64